Therefore, TOPK may be a potential cancer-specific biomarker, and serves as a druggable cancer target with minimal harm to normal tissue (Bellayr et al., 2016; Hayashi et al., 2018; Herbert et al., 2018; Pirovano et al., 2020). This evidence concerns the gene PBK and cancer.